NCT00154492

Use of NovoSeven® in Active Variceal Bleeding

Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 265 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

Conditions

• Acquired Bleeding Disorder
• Cirrhosis

Interventions

Type	Name	Description
DRUG	activated recombinant human factor VII

Timeline

• Start date: 2004-04-01
• Primary completion: 2006-08-01
• Completion: 2006-08-01
• First posted: 2005-09-12
• Last updated: 2017-01-13

Locations

44 sites across 12 countries: Austria, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Poland, Spain, Taiwan, United Kingdom